Smarter decisions, better outcomes: How a new molecular test improves patient care

Smarter decisions, better outcomes: How a new molecular test improves patient care Oliver Bathe, Professor of Surgery and Oncology at the University of Calgary and CEO of Qualisure Diagnostics, examines how a new molecular test can lead to smarter decisions and better patient care outcomes in his third article. For people diagnosed with papillary thyroid cancer (PTC), treatment decisions often must be made with limited information. Patients may be asked to choose between major surgery, radioactive iodine, or active monitoring – all without knowing how aggressive their cancer truly is. Physicians do their best using tumor size, imaging, and pathology, but these tools offer only a partial picture.